XORTX Therapeutics Inc (XRTX) Stock Analysis

XORTX Therapeutics Inc (XRTX) is a publicly traded company in the HEALTHCARE sector. It trades at $2.23, carries a market capitalization of $3.82M. This page summarizes the public market data, fundamentals, and frequently asked questions for XRTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

XORTX Therapeutics Inc currently has a Neutral sentiment score of -0.10.

About XORTX Therapeutics Inc

XORTX Therapeutics Inc. is a Vancouver-based biopharmaceutical company dedicated to developing innovative therapies for progressive kidney diseases and related metabolic disorders, including hypertension and diabetic nephropathy. The company is advancing its proprietary drug candidates through clinical development with a focus on addressing significant unmet medical needs and improving patient outcomes. By leveraging cutting-edge research and forming strategic partnerships, XORTX aims to succ...

GNG Research Analysis

GNG Research scores XORTX Therapeutics Inc (XRTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for XRTX.

Frequently Asked Questions

Does XRTX pay dividends?

XORTX Therapeutics Inc (XRTX) does not currently pay a regular dividend.

What is XRTX's market cap?

XORTX Therapeutics Inc (XRTX) has a market capitalization of $3.82M with a current stock price of $2.23.